Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

Patients with resectable non–small-cell lung cancer had a greater response and longer event-free survival with preoperative durvalumab plus chemotherapy and adjuvant durvalumab than with chemotherapy alone.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-11, Vol.389 (18), p.1672-1684
Hauptverfasser:	Heymach, John V., Harpole, David, Mitsudomi, Tetsuya, Taube, Janis M., Galffy, Gabriella, Hochmair, Maximilian, Winder, Thomas, Zukov, Ruslan, Garbaos, Gabriel, Gao, Shugeng, Kuroda, Hiroaki, Ostoros, Gyula, Tran, Tho V., You, Jian, Lee, Kang-Yun, Antonuzzo, Lorenzo, Papai-Szekely, Zsolt, Akamatsu, Hiroaki, Biswas, Bivas, Spira, Alexander, Crawford, Jeffrey, Le, Ha T., Aperghis, Mike, Doherty, Gary J., Mann, Helen, Fouad, Tamer M., Reck, Martin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - therapeutic use Administration, Intravenous Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis B7-H1 Antigen - administration & dosage B7-H1 Antigen - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy Clinical medicine Clinical practice guidelines Combined Modality Therapy Critical Care Critical Care General Death Hematology Humans Immunotherapy Lung Cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - surgery Lymphatic system Medical screening Monoclonal antibodies Neoplasm Recurrence, Local - drug therapy Non-small cell lung carcinoma Oncology PD-L1 protein Placebos Pulmonary Radiation therapy Small cell lung carcinoma Statistical analysis Surgery Surgery General Targeted cancer therapy Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with resectable non–small-cell lung cancer had a greater response and longer event-free survival with preoperative durvalumab plus chemotherapy and adjuvant durvalumab than with chemotherapy alone.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2304875